search
Back to results

Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation

Primary Purpose

Chronic Obstructive Pulmonary Disease

Status
Unknown status
Phase
Phase 4
Locations
Mexico
Study Type
Interventional
Intervention
BiPAP Pro 2, Phillips Respironics
CPAP sham
Sponsored by
National Institute of Respiratory Diseases, Mexico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Chronic Obstructive Pulmonary Disease focused on measuring acute exacerbation of COPD number, acute exacerbation of COPD severity

Eligibility Criteria

45 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical and spirometric diagnosis for COPD (FEV1/FVC <70%)
  • Clinical phenotype of frequent exacerbations
  • Must sign the informed consent
  • Former smokers
  • Stable COPD
  • FEV1 <35%
  • Optimal medical treatment

Exclusion Criteria:

  • OSAS diagnosis
  • Other indications for non invasive mechanical ventilation
  • Arterial pressure for dioxide carbon >45mmHg
  • Lung cancer
  • Impossibility for doing spirometry or going to the medical visits
  • Be included in another study

Sites / Locations

  • National Institute of Respiratory Diseases

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

cpap sham

high-intensity NIMV

Arm Description

non invasive mechanical ventilation type cpap sham manoeuver

Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)

Outcomes

Primary Outcome Measures

acute exacerbations of Chronic Obstructive Pulmonary Disease frequency
It will be calculated the exacerbation/year-patien rate and will be compared between groups
acute exacerbation of chronic obstructive pulmonary disease severity
It will be measured the rate of AECOPD with hospitalary and Intensive Care Unity requirement

Secondary Outcome Measures

lymphocyte subpopulations Th-1 and Th-17
It will be measured the lymphocyte subpopulations like Th-1 and Th-17
six-minute walking test
Forced expiratory volume in first second (FEV1) and forced expiratory capacity
Maximal inspiratory pressure and maximal expiratory pressure
gas exchange response (carbon and oxygen dioxide arterial pressure)
Health related quality of life
anxiety and depression measures (HAD and Beck Questionnaires)
echocardiographic parameters
survival
IL-1 and IL-6 cytokines
it will be measured the level of interleukines 1 and 6(IL-1 and IL-6)

Full Information

First Posted
October 20, 2011
Last Updated
May 22, 2015
Sponsor
National Institute of Respiratory Diseases, Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT01481727
Brief Title
Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation
Official Title
Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Unknown status
Study Start Date
December 2011 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
December 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Institute of Respiratory Diseases, Mexico

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy of high-intensity non invasive mechanical ventilation (during one year to reduce the severity and frequency of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in patients with frequent AECOPD (frequent exacerbations defined more two or more AECOPD) and in GOLD IV stage (very severe COPD). The design is a randomised, double blind and controled with placebo (sham maneuver) clinical trial.
Detailed Description
Background: There are many previous studies (no controlled trials or observational studies)that demonstrated minimal benefits (on gas exchange and marginal effect over exacerbations frequency) with the use of non invasive mechanical ventilation, in BiPAP modality with IPAP pressures <18H2ocm (low intensity), in COPD patients. In subsequent years there were controled trials that concluded that there was no benefits with the use of non invasive mechanical ventilation on BiPAP mode in COPD patients ( It should be mentioned that in most trials were used low inspiratory pressure levels, that is called low-intensity non invasive mechanical ventilation). However, there are other recent studies that described some benefits of high intensity Bilevel modality of non invasive mechanical ventilation (inspiratory pressures >18cmH2O) specially on gas exchange, quality of life and functional status. There are some issues that do not yet have a clear answer like the optimal inspiratory pressure (IPAP) or the ventilation modality (BIPAP or other) to obtain the maximal benefit on COPD patients. Additionally, is not clear also if the use of non invasive mechanical ventilation on COPD patients helps to reduce the frequency and severity of acute exacerbations of COPD (AECOPD). This study have some characteristics that are different to the previous reports: The inclusion of patients with frequent exacerbations phenotype (and therefore worst prognosis patients)that there are no included in previous trials The intervention maneuver that is bilevel modality of non invasive mechanical ventilation at hig-intensity pressure (>18H2Ocm and <24H2Ocm) The use of placebo maneuver (CPAP "Sham") The home titration in three phases, over a week The long-term use of the intervention and sham maneuver

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease
Keywords
acute exacerbation of COPD number, acute exacerbation of COPD severity

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
cpap sham
Arm Type
Placebo Comparator
Arm Description
non invasive mechanical ventilation type cpap sham manoeuver
Arm Title
high-intensity NIMV
Arm Type
Active Comparator
Arm Description
Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
Intervention Type
Device
Intervention Name(s)
BiPAP Pro 2, Phillips Respironics
Other Intervention Name(s)
high intensity non invasive ventilation, high intensity bilevel
Intervention Description
mechanical ventilation type bilevel at high intensity (>18mmHg) for at least six hours, nocturnal ventilation.
Intervention Type
Device
Intervention Name(s)
CPAP sham
Other Intervention Name(s)
placebo CPAP, sham non invasive ventilation
Intervention Description
CPAP sham maneuver (IPAP less or equal to 4cmH2O)
Primary Outcome Measure Information:
Title
acute exacerbations of Chronic Obstructive Pulmonary Disease frequency
Description
It will be calculated the exacerbation/year-patien rate and will be compared between groups
Time Frame
1 year
Title
acute exacerbation of chronic obstructive pulmonary disease severity
Description
It will be measured the rate of AECOPD with hospitalary and Intensive Care Unity requirement
Time Frame
1 year
Secondary Outcome Measure Information:
Title
lymphocyte subpopulations Th-1 and Th-17
Description
It will be measured the lymphocyte subpopulations like Th-1 and Th-17
Time Frame
1 year
Title
six-minute walking test
Time Frame
1 year
Title
Forced expiratory volume in first second (FEV1) and forced expiratory capacity
Time Frame
1 year
Title
Maximal inspiratory pressure and maximal expiratory pressure
Time Frame
1 año
Title
gas exchange response (carbon and oxygen dioxide arterial pressure)
Time Frame
1 year
Title
Health related quality of life
Time Frame
one year
Title
anxiety and depression measures (HAD and Beck Questionnaires)
Time Frame
one year
Title
echocardiographic parameters
Time Frame
one year
Title
survival
Time Frame
one year
Title
IL-1 and IL-6 cytokines
Description
it will be measured the level of interleukines 1 and 6(IL-1 and IL-6)
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical and spirometric diagnosis for COPD (FEV1/FVC <70%) Clinical phenotype of frequent exacerbations Must sign the informed consent Former smokers Stable COPD FEV1 <35% Optimal medical treatment Exclusion Criteria: OSAS diagnosis Other indications for non invasive mechanical ventilation Arterial pressure for dioxide carbon >45mmHg Lung cancer Impossibility for doing spirometry or going to the medical visits Be included in another study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
RAUL HUMBERTO SANSORES MARTINEZ, MMS and MD
Organizational Affiliation
NATIONAL INSTITUTE OF RESPIRATORY DISEASES
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institute of Respiratory Diseases
City
Mexico City
ZIP/Postal Code
14080
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
19213769
Citation
McEvoy RD, Pierce RJ, Hillman D, Esterman A, Ellis EE, Catcheside PG, O'Donoghue FJ, Barnes DJ, Grunstein RR; Australian trial of non-invasive Ventilation in Chronic Airflow Limitation (AVCAL) Study Group. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009 Jul;64(7):561-6. doi: 10.1136/thx.2008.108274. Epub 2009 Feb 12.
Results Reference
background
PubMed Identifier
12358325
Citation
Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N; Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002 Sep;20(3):529-38. doi: 10.1183/09031936.02.02162001. Erratum In: Eur Respir J. 2002 Dec;20(6):1617.
Results Reference
background
PubMed Identifier
11115443
Citation
Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, Santolaria F. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest. 2000 Dec;118(6):1582-90. doi: 10.1378/chest.118.6.1582.
Results Reference
background
PubMed Identifier
8756806
Citation
Lin CC. Comparison between nocturnal nasal positive pressure ventilation combined with oxygen therapy and oxygen monotherapy in patients with severe COPD. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):353-8. doi: 10.1164/ajrccm.154.2.8756806.
Results Reference
background
PubMed Identifier
19277252
Citation
Windisch W, Haenel M, Storre JH, Dreher M. High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. Int J Med Sci. 2009;6(2):72-6. doi: 10.7150/ijms.6.72. Epub 2009 Feb 27.
Results Reference
background
PubMed Identifier
20388753
Citation
Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax. 2010 Apr;65(4):303-8. doi: 10.1136/thx.2009.124263.
Results Reference
background
PubMed Identifier
16100151
Citation
Windisch W, Kostic S, Dreher M, Virchow JC Jr, Sorichter S. Outcome of patients with stable COPD receiving controlled noninvasive positive pressure ventilation aimed at a maximal reduction of Pa(CO2). Chest. 2005 Aug;128(2):657-62. doi: 10.1378/chest.128.2.657.
Results Reference
background
PubMed Identifier
17686094
Citation
Budweiser S, Hitzl AP, Jorres RA, Heinemann F, Arzt M, Schroll S, Pfeifer M. Impact of noninvasive home ventilation on long-term survival in chronic hypercapnic COPD: a prospective observational study. Int J Clin Pract. 2007 Sep;61(9):1516-22. doi: 10.1111/j.1742-1241.2007.01427.x.
Results Reference
background

Learn more about this trial

Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation

We'll reach out to this number within 24 hrs